ERBB2 and breast carcinoma: Moreover, the Responsify dataset, in which both RPPA and RNA expression data were available for patients with HER2-positive breast cancer who were treated with trastuzumab in the adjuvant setting with the more standard duration of one year, enabled us to perform an external validation of the data in this specific subset of patients.